Clinical trial · Interventional
Cancer Prevention and Early Detection Among the Homeless Population: The Health Navigator Model
Cancer Prevention and Early Detection Among the Homeless Population in Europe: Co-adapting and Implementing the Health Navigator Model
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prevention and early detection are key for the decrease of cancer-related mortality. However, socially deprived population groups don't have the privilege of unburdened access to the healthcare system. The EU-funded CANCERLESS project aims to develop an evidence-based, patient-centred innovation that reinforces patients through health education and social support and fosters timely access to primary and secondary prevention services. Based on the combination of the tested Patient Navigator Model and the Patient Empowerment Model, CANCERLESS will develop the Health Navigator Model for Europe, addressed to the underserved population.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Health Navigator Model | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- People experiencing homelessness
- description
- All homeless adults, aged 18 years and over, who visit the CANCERLESS pilot sites will be asked to participate (convenience sampling). We define individuals as being homeless if they fall under one of the categories listed in the European typology of homelessness and housing exclusion.
- interventionNames
- Other: Health Navigator Model
Primary outcomes (3)
- measure
- Clinical utility/effectiveness
- timeFrame
- 18 months
- description
- The first objective of the CANCERLESS evaluation is to determine the clinical utility/effectiveness of the Health Navigator Model intervention on the health promotion and cancer primary and secondary prevention among people experiencing homelessness. Effectiveness refers to the likelihood that a certain protocol (in this case the Health Navigator Model) will benefit users in a certain population (in this case people experiencing homelessness) by resulting in an improved health outcome. Therefore, the clinical utility/effectiveness evaluation will include the assessment of the differences between baseline and follow-up measurements, especially on health outcomes among those people experiencing homelessness that participate in the project.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older * No diagnosed cancer * Any category of the European Typology of Homelessness and housing exclusion applies * Sufficient knowledge of language Exclusion Criteria: * Persons who cannot give consent due to diminished capacity * Persons who do not provide informed consent * Known cancer diagnosis * Cancer survivorship
References
Publications (2)
- DERIVEDFragner T, Alhambra-Borras T, Donate-Martinez A, Blanes-Selva V, Garcia-Gomez JM, Gawronska J, Moudatsou M, Tabaki I, Belogianni K, Karnaki P, Varade MR, Trenado RG, Barrio-Cortes J, Smith L, Gil-Salmeron A, Grabovac I. Empowerment and quality of life through cancer prevention in people experiencing homelessness: evaluating the Health Navigator Model. Health Qual Life Outcomes. 2026 Jul 19. doi: 10.1186/s12955-026-02588-8. Online ahead of print. PMID 42471660
- DERIVEDCarmichael C, Schiffler T, Smith L, Moudatsou M, Tabaki I, Donate-Martinez A, Alhambra-Borras T, Kouvari M, Karnaki P, Gil-Salmeron A, Grabovac I. Barriers and facilitators to health care access for people experiencing homelessness in four European countries: an exploratory qualitative study. Int J Equity Health. 2023 Oct 6;22(1):206. doi: 10.1186/s12939-023-02011-4. PMID 37803317